On the FDA's Fast Track and in phase III testing is the company's BAY 43-9006, a small molecule RAF kinase and VEGF inhibitor that inhibits tumor growth for patients with metastatic renal cell carcinoma (advanced kidney cancer).

FORBES: Beware Of Biotechs At Cancer-Cure Prices